null

null

null

null

null

null

null

null

null

Minimal long-term debt; primarily equity-funded via ATM offerings; a 200bps rate rise marginally increases minimal interest expense on any credit facility

Low direct sensitivity; primary risk is higher cost of future equity dilution and reduced biotech investor appetite in rising rate environment

Medium intensity; US-China trade tariffs on metals and components disrupt supply chains.

Single-use diagnostic consumables from Asia-Pacific manufacturers; reagent supply concentration in China and Taiwan represents top chokepoints

Negligible; virtually all revenue is US-domestic; no material sovereign currency devaluation exposure currently

Operates almost exclusively in the US; no meaningful international revenue markets; currency devaluation risk is effectively zero

Medium intensity; commodities: Steel, Aluminum, Copper, Crude Oil (fuel), Rare Earth Elements, Plastics/Resins; geopolitical: US-China trade tariffs on metals and components disrupt supply chains.

High dependency on Broncus Medical for bronchoscopy platform partnership and specific reagent suppliers; substitution would require regulatory re-validation

Diagnostics/MedTech; cloud infrastructure is not central to core lab operations; 30-day termination would disrupt data management but not core assay delivery

Fee-for-service diagnostic test provider with hospital and clinical lab clients; cloud dependency is administrative, not product-critical

Moderate API coupling risk; lab information system integrations create moderate switching friction but are not deeply proprietary

Low Howey risk; revenue model is fee-for-service diagnostic billing; no investment contract characteristics present

Medium

Moderate HIPAA exposure as primary concern; GDPR risk minimal given US-only operations; CCPA compliance required for any California patient data

Low; niche early lung cancer diagnostics market with limited market share; no dominant position triggering antitrust scrutiny

Medium burden; regimes: FAA, DOT, OSHA, EPA, ITAR, FTC; Export controls and defense procurement rules create contract concentration risk.

Predominantly transactional fee-for-service per CyPath Lung test; minimal recurring contract revenue; estimated >90% transactional

Per-test billing reimbursed via Medicare/Medicaid and commercial payers; reimbursement rate ~$1,882 per CyPath Lung test under existing codes

Pricing set by CPT reimbursement codes; limited ability to unilaterally raise prices; payer contract negotiations constrain pricing power significantly

Low; reimbursement-rate-dependent pricing with CMS and commercial payers controlling effective price ceiling

0.1% Gross Margin (Thin (<20%))

Moderate free-rider risk low; however, physician adoption is slow and clinicians may revert to standard CT-only protocols without active detailing

Revenue growth is partially headcount-linear; lab technicians and sales reps must scale with test volume; some sublinearity in G&A functions

Moderately sublinear at scale; reagent and lab processing costs are variable but G&A leverage is achievable; estimated 60-70% incremental margins at maturity

Not applicable; company is not a franchise model

At 10x scale, CAC must decrease via payer coverage expansion and physician education efficiency; current sales-force-intensive model is not yet optimized

Weak network effects; diagnostic data accumulation could strengthen algorithm performance but no direct user-to-user network effect exists

-135.6% Return on Assets (Negative equity)

Moderate; lung cancer screening is semi-elective but Medicare-reimbursed, providing partial recession insulation; commercial payer mix adds cyclical risk

Pulmonologists, thoracic surgeons, and high-risk lung cancer screening clinics ordering CyPath Lung tests

Hospital systems and independent clinical laboratories; early-stage customer concentration risk is high given limited commercial footprint

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "23-0000 Legal Occupations", "33-0000 Protective Service Occupations", "37-0000 Building and Grounds Cleaning and Maintenance Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "47-0000 Construction and Extraction Occupations", "49-0000 Installation, Maintenance, and Repair Occupations", "51-0000 Production Occupations", "53-0000 Transportation and Material Moving Occupations"]

0.3 (HIL — ~30% of characteristic roles agent-automatable)

1.0% CapEx / Revenue (Low-CapEx Asset-Light)

0001712762

BIAF